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Abstract: The aim of this study was to investigate the management and outcome in the post-laser
twin anemia polycythemia sequence (TAPS). Data of the international TAPS Registry, collected
between 2014 and 2019, were used for this study. The primary outcomes were perinatal mortality
and severe neonatal morbidity. Secondary outcomes included a risk factor analysis for perinatal
mortality and severe neonatal morbidity. A total of 164 post-laser TAPS pregnancies were included,
of which 92% (151/164) were diagnosed antenatally and 8% (13/164) postnatally. The median number
of days between laser for TTTS and detection of TAPS was 14 (IQR: 7–28, range: 1–119). Antenatal
management included expectant management in 43% (62/151), intrauterine transfusion with or
without partial exchange transfusion in 29% (44/151), repeated laser surgery in 15% (24/151), selective
feticide in 7% (11/151), delivery in 6% (9/151), and termination of pregnancy in 1% (1/151). The median
gestational age (GA) at birth was 31.7 weeks (IQR: 28.6–33.7; range: 19.0–41.3). The perinatal mortality
rate was 25% (83/327) for the total group, 37% (61/164) for donors, and 14% (22/163) for recipients
(p < 0.001). Severe neonatal morbidity was detected in 40% (105/263) of the cohort and was similar for
donors (43%; 51/118) and recipients (37%; 54/145), p = 0.568. Independent risk factors for spontaneous
perinatal mortality were antenatal TAPS Stage 4 (OR = 3.4, 95%CI 1.4-26.0, p = 0.015), TAPS donor
status (OR = 4.2, 95%CI 2.1–8.3, p < 0.001), and GA at birth (OR = 0.8, 95%CI 0.7–0.9, p = 0.001). Severe
neonatal morbidity was significantly associated with GA at birth (OR = 1.5, 95%CI 1.3–1.7, p < 0.001).
In conclusion, post-laser TAPS most often occurs within one month after laser for TTTS, but may
develop up to 17 weeks after initial surgery. Management is mostly expectant, but varies greatly,
highlighting the lack of consensus on the optimal treatment and heterogeneity of the condition.
Perinatal outcome is poor, particularly due to the high rate of perinatal mortality in donor twins.
Keywords: monochorionic twins; twin anemia polycythemia sequence; TAPS; twin-twin transfusion
syndrome; TTTS; laser surgery; management; perinatal mortality; fetal demise; neonatal morbidity
1. Introduction
The twin anemia polycythemia sequence (TAPS) can arise from chronic unbalanced feto-fetal
transfusion through minuscule placental anastomoses in monochorionic twins, leading to anemia in the
TAPS donor and polycythemia in the TAPS recipient [1]. Unlike twin-twin transfusion syndrome (TTTS),
TAPS develops in the absence of the twin oligohydramnios-polyhydramnios sequence. The iatrogenic
form of TAPS, post-laser TAPS, can develop in 2–16% after laser surgery for TTTS due to the presence of
minuscule residual anastomoses [2–4]. The rate of post-laser TAPS can be reduced by using the Solomon
technique instead of the selective laser technique (3% vs. 16%, respectively) [2]. With this approach,
the entire placental vascular equator is laser photocoagulated, thereby blocking all anastomoses,
even the miniscule ones that may not be visualized. Although the rate of residual anastomoses has
significantly dropped after the implementation of the Solomon technique, post-laser TAPS may still
occur [2,5,6]. Options to manage post-laser TAPS include expectant management, preterm delivery,
intrauterine transfusion (IUT) with or without a partial exchange transfusion (PET), fetoscopic laser
surgery, and selective feticide [7]. The best treatment has not been established. The technical feasibility
of a second intrauterine intervention may be limited due to complications that have arisen from the
initial laser procedure for TTTS, such as amnion-chorion separation or preterm premature rupture
of the membranes (PPROM). For informed decision making regarding the preferred intervention,
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it is crucial to have insight into perinatal outcome of post-laser TAPS twins. Due to the rarity of the
complication, perinatal outcome is insufficiently investigated, and available information is based on
small cohort studies. To expand our knowledge on TAPS, we set up the TAPS Registry, an international
collaboration aimed at collecting data on diagnosis, treatment, and outcome in TAPS twins.
In the current study, the data from this TAPS Registry were used to (1) characterize diagnosis,
treatment modalities, and outcome in post-laser TAPS twins, (2) to compare perinatal outcome between
TAPS donors and recipients, and (3) to investigate potential risk factors for adverse perinatal outcome.
2. Experimental Section
The TAPS Registry, established in 2014, was a web-based registry for anonymous data collection
(www.tapsregistry.org). Fetal therapy centers across the world were invited to participate. Participating
centers were provided with personal credentials to enter the data of their TAPS cases into the online
registry. Between 2014 and 2019, seventeen specialized fetal therapy centers contributed to data
collection (see Appendix A).
All monochorionic twin pregnancies diagnosed with post-laser TAPS were considered eligible
for this study. Pregnancies with spontaneous TAPS were excluded and were described in a separate
study [8].
Antenatal diagnosis of TAPS was based on discordant middle cerebral artery peak systolic velocity
(MCA-PSV) measures, with an increased MCA-PSV (>1.5 multiples of the median (MoM)) in the
TAPS donor, indicative of fetal anemia, combined with a decreased MCA-PSV measure (<1.0 MoM)
in the TAPS recipient, indicative of fetal polycythemia [9]. Postnatal diagnosis was reached by
the presence of an inter-twin hemoglobin difference > 8.0 g/dL combined with at least one of the
following: a reticulocyte count ratio > 1.7 or the presence of only minuscule vascular anastomoses
(diameter < 1 mm) detected through color dye injection of the placenta [10,11]. Cases that were
diagnosed with TAPS within one week after laser surgery for TTTS were excluded from the study,
unless TAPS persisted. We did this as a large MCA-PSV discrepancy shortly after laser is likely to be a
result of hemodynamic re-equilibration and is not based on TAPS [12].
The following information was obtained from local medical records: gravidity, parity, location of
the placenta, moment of diagnosis (antenatal or postnatal), gestational age (GA) at diagnosis, TAPS
stage at diagnosis, and the presence of additional ultrasound findings including "starry-sky liver” in the
recipient and/or a difference in placental echogenicity. The severity of antenatal TAPS was determined
according to the previously published staging system by Slaghekke et al. [13]. For post-laser TAPS
specifically, the following data regarding preceding TTTS were collected: Quintero stage, GA at laser,
laser technique, operator’s opinion on completeness of the laser procedure, and TTTS-donor-recipient
role. In addition, the antenatal management for TAPS was recorded, including expectant management,
delivery (defined as a delivery within 7 days after diagnosis), IUT (± PET), fetoscopic laser surgery,
selective feticide, and termination of pregnancy (TOP). Furthermore, information on placental color
dye injection was collected, including classification of the type (arterio-venous (AV), veno-arterial
(VA), arterio-arterial (AA), veno-venous (VV)), and the number and size of anastomoses. Perinatal
outcome measures included: TAPS donor/recipient status, birth weight, hemoglobin and reticulocyte
values, treatment with blood transfusion or partial exchange transfusion on Day 1, the presence of
severe neonatal morbidity and/or severe cerebral injury, and the occurrence of perinatal mortality.
Primary outcomes were perinatal mortality and severe neonatal morbidity. Perinatal mortality
was defined as fetal demise or neonatal death within 28 days after birth. In the context of selective
feticide or TOP, a distinction was made between spontaneous fetal demise and intended fetal demise.
Severe neonatal morbidity was defined as the presence of at least one of the following, diagnosed within
28 days after birth or prior to discharge: respiratory distress syndrome requiring mechanical ventilation
and surfactant, patent ductus arteriosus requiring treatment, necrotizing enterocolitis ≥ Stage 2 [14],
retinopathy of prematurity ≥ Stage 3 [15], amniotic band syndrome, ischemic limb injury, or severe
cerebral injury. Severe cerebral injury was diagnosed in case of one of the following abnormalities
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was identified on cerebral imaging: intraventricular hemorrhage ≥ Stage 3 [16], ventricular dilatation
(including post-hemorrhagic ventricular dilatation) [17], cystic periventricular leukomalacia ≥ Grade
2 [18], porencephalic or parenchymal cysts, arterial infarction, or other severe cerebral lesions associated
with an adverse outcome.
Secondary outcomes included diagnosis- and therapy-related characteristics, hematological
and placental characteristics, and a risk factor analysis for spontaneous perinatal mortality and
severe neonatal morbidity. Cases with intended fetal demise in the context of selective feticide
or termination of pregnancy were excluded for the risk factor analysis for spontaneous perinatal
mortality. Since TAPS cases may be managed according to different strategies in one pregnancy,
management-group assignment was based on the first treatment that was performed. The following
parameters were investigated in the univariate risk analysis: GA at diagnosis of TAPS, GA at laser
for TTTS, days between laser for TTTS and development of TAPS, Quintero stage, antenatal TAPS
stage, persistence of TTTS-TAPS donor-recipient status, type of antenatal management, and GA at
birth (in weeks). For antenatal TAPS stage, the highest recorded antenatal TAPS stage was selected. In
case of TAPS Stage 5, the highest TAPS stage before Stage 5 was used. For the risk factor analysis for
severe neonatal morbidity, two more parameters were added: severe growth restriction defined as
birth weight < 3rd centile and the presence of postnatal TAPS.
The following additional outcomes were determined: inter-twin hemoglobin difference (highest
hemoglobin value–lowest hemoglobin value), reticulocyte count ratio (highest reticulocyte value
(‰)/lowest reticulocyte value (‰)), the presence of severe growth restriction (defined as a birth
weight < 3rd centile according to Hoftiezer [19]), postnatal TAPS stage (according to Slaghekke [7]),
and the configuration of anastomosis type per TAPS placenta.
Statistical analyses were carried out using SPSS Version 25.0 (IBM, Armonk, NY, USA). Data
are presented as the mean ± standard deviation (SD) or as median and interquartile range (IQR)
and/or range (minimum-maximum), as appropriate. A p-value < 0.05 was considered statistically
significant. Differences between donors and recipients were calculated using the paired t-test for
normally distributed continuous outcomes. To account for the fact that observations between co-twins
are not independent, the Generalized Estimated Equation module was executed for analyses per
fetus or neonate. Potential risk factors were checked for correlation using Spearman’s rank test (R).
A correlation coefficient R > (−) 0.7 was considered to indicate a strong relationship between the
factors. Potential risk factors for perinatal mortality and severe neonatal morbidity were assessed in
a univariate logistic regression model. A multivariate logistic regression model was applied to the
variables that showed significant association in the univariate analysis. Results are expressed as odds
ratios (OR) with 95% confidence intervals (CI).
3. Results
Of the 422 TAPS cases entered into the TAPS Registry, two-hundred forty-nine (59%) were
spontaneous TAPS and were excluded from the study. The remaining 173 (41%) were post-laser TAPS
and eligible for the study. In eight post-laser TAPS cases, TAPS was diagnosed within one week
after laser for TTTS. As TAPS did not persist one week after laser surgery for TTTS, these cases were
excluded. One case was excluded based on TAPS being diagnosed at Stage 5. A total of 164 post-laser
TAPS cases were included in the analysis for the current study.
TAPS was diagnosed antenatally in 92% (151/164) and only postnatally in 8% (13/164) of the group
(Table 1). Laser for TTTS (prior to post-laser TAPS) was performed using the Solomon technique in 37%
(60/164) and the selective technique in 63% (104/164). The operating surgeon assumed that the laser
for TTTS was complete in 81% (126/156) of post-laser TAPS cases, in 74% (43/58) of cases treated with
the Solomon technique, and in 85% (83/98) of cases treated with the selective technique. Reasons for
incomplete laser were: poor visibility (n = 11), fetal position (n = 7), placental position (n = 5), bleeding
(n = 2), velamentous anastomoses (n = 1), vomiting of patient (n = 1), and not specified (n = 3). In half
of the antenatally detected TAPS cases, TAPS developed within 14 days (IQR: 7–28; range 1–119) after
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laser treatment for TTTS. Figure 1 depicts time between laser for TTTS and the diagnosis of post-laser
TAPS for all antenatally diagnosed cases. In 45% (73/161) of cases, TTTS donors became TAPS donors.
Antenatal management included expectant management in 43% (62/151), IUT (± PET) in 29% (44/151),
laser reintervention in 15% (24/151), selective feticide in 7% (11/151), delivery in 6% (9/151), and TOP in
1% (1/151) (Table 2).
Table 1. Baseline characteristics for the post-laser twin anemia polycythemia sequence.
Post-Laser TAPS
(N = 164 Pregnancies, 328 Fetuses)
Gravidity 2 (1–3)
Parity 0 (0–1)
Antenatal diagnosis of TAPS 151/164 (92)
Location of placenta
Anterior 72/164 (44)
Posterior 86/164 (52)
Other † 6/164 (4)
TTTS stage ‡
Q1 20/159 (13)
Q2 75/159 (47)
Q3 59/159 (37)
Q4 5/159 (3)
Solomon technique for TTTS laser 60/164 (37)
GA at laser for TTTS 20.6 (18.0–23.0)
Time between laser and post-laser TAPS (days) 14 (7–28)
Persistence of TTTS-TAPS donor-recipient role § 73/161 (45)
Laser for TTTS complete (surgeon’s opinion) ¶ 126/156 (81)
Data are presented as n/N (%) or the median (IQR). † Other types of placental position included: partly anterior and
partly posterior (n = 1) and partly fundal (n = 1) lateral left (n = 2) and lateral right (n = 2). ‡ Five missing values.
§ Three missing values. ¶ Eight missing values. TAPS, twin anemia polycythemia sequence; TTTS, twin-twin
transfusion syndrome; Q, Quintero; GA, gestational age.
Table 2. Diagnosis- and management-related characteristics for the post-laser twin anemia polycythemia sequence.
Post-Laser TAPS
(N = 164 Pregnancies, 328 Fetuses)
GA at diagnosis 23.1 (20.4–25.9)
TAPS stage at diagnosis
1 43/151 (28)
2 69/151 (48)
3 27/151 (17)
4 12/151 (8)
Highest TAPS stage
1 22/151 (15)
2 62/151(40)
3 26/151 (16)
4 22/151 (14)
5 19/151 (15)
Presence of additional ultrasound markers †
Starry-sky liver (recipient) 56/141 (40)
Difference in placental echogenicity 35/151 (23)
Antenatal management
Expectant management 62/151 (43)
Delivery 9/151 (6)
IUT (± PET) 44/151 (29)
Laser surgery 24/151 (15)
Selective feticide 11/151 (7)
Termination of pregnancy 1/151 (1)
Female ‡ 162/308 (53)
Cesarean § 206/326 (63)
Data are the median (IQR) or n/N (%). Except for “female” and “cesarean”, all other parameters are presented for
antenatally diagnosed post-laser TAPS cases only (N = 151).† In 10 cases, the presence of a starry-sky liver was not
assessed. ‡ Twenty missing values. § Two missing values.TAPS, twin anemia polycythemia; GA, gestational age;
IUT, intrauterine transfusion; PET, partial exchange transfusion.
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Figure 1. Weeks between fetoscopic laser surgery for twin-twin transfusion syndrome and diagnosis of post-laser twin anemia polycythemia sequence.
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In total, 51% (84/164) of post-laser TAPS placentas were injected with color dye (Table 3). Of the 84
injected placentas, ten cases were treated with laser reintervention, and 74 cases were not treated with
laser reintervention. In placentas not treated with laser reintervention, the median total number of
anastomoses was one (IQR: 0–1), and 55% (40/74) had only AV anastomoses running in one direction.
AA and VV anastomoses were detected in 8% (6/74) and 7% (5/74) of the group, respectively. In ten TAPS
placentas, no residual anastomoses were found after color dye injection: five placentas belonged to
cases with spontaneous resolution of TAPS after expectant management or treatment with IUT (±PET),
and the other five belonged to cases with TAPS confirmed both antenatally and postnatally. Residual
anastomoses were found in 40% (4/10) of post-laser TAPS cases treated with laser reintervention. Three
cases with residual anastomoses had only one minuscule AV anastomosis, and the fourth had one
single minuscule AA anastomosis. Out of the four cases with residual anastomoses, two cases had
confirmed postnatal TAPS, one case had a double fetal demise after reintervention with laser, and
one case showed an inter-twin hemoglobin difference of 8 g/dL (borderline TAPS) and had a low
reticulocyte count ratio, but required a blood transfusion and partial exchange transfusion on day 1.
Table 3. Characteristics for placentas not treated with laser reintervention for the post-laser twin
anemia polycythemia sequence.
Injected Post-Laser
TAPS Placentas
(N = 74)
Total number of anastomoses 1 (1–2)
Number of AV anastomoses 1 (0–1)
Number of VA anastomoses 0 (0–1)
Number of AA anastomoses 0 (0–0)
Number of VV anastomoses 0 (0–0)
Presence of anastomoses
Presence of AV/VA anastomoses 58/74 (80)
Presence of AA anastomoses 6/74 (8)
Presence of VV anastomoses 5/74 (7)
Type of anastomoses per placenta
No anastomoses 10/74 (14)
AV (one direction) 40/74 (54)
AVs (both directions) 14/74 (19)
AV/VA and AA 3/74 (4)
AV/VA and VV 2/74 (3)
Only AA 2/74 (3)
Only VV 2/74 (3)
AV/VA, AA and VV 1/74 (1)
All anastomoses diameter < 1 mm 62/64 (97)
Data are the median (IQR) or n/N (%). TAPS, twin anemia polycythemia; TTTS, twin-twin transfusion syndrome;
AV, arterio-venous; VA, veno-arterial; AA, arterio-arterial; VV, veno-venous.
Table 4 provides information on the perinatal outcome of post-laser TAPS twins, separated for
TAPS donors and recipients. Median GA at birth was 31.7 weeks (IQR: 28.6–33.7, range 19.0–41.3).
TAPS donors had significantly lower mean birth weights than TAPS recipients, 1346 g ± 525 g vs.
1533 g ± 588 g p < 0.001. Fetal demise occurred in 17% (56/327) of the group, either spontaneously in
10% (33/327) or intentionally in 7% (23/327). TAPS donors had a higher risk of fetal demise than TAPS
recipients, both for spontaneous fetal demise (15% (25/164) vs. 5% (8/163); p < 0.001) and intended fetal
demise (11% (18/164) vs, 3% (5/163); p = 0.007). The rate of neonatal mortality was 10% (27/271) and
was higher in TAPS donors than in TAPS recipients, 15% (18/121) vs. 6% (9/150), respectively (p = 0.008).
Overall, perinatal mortality (including intended demise) occurred in 25% (83/327) of TAPS twins, in
37% (61/164) of TAPS donors, and 14% (22/163) of TAPS recipients, respectively (p < 0.001). Severe
neonatal morbidity was diagnosed in 40% (105/263) of liveborn twins and was similar for TAPS donors
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(43%; 51/118) and TAPS recipients (37%; 54/145), p = 0.568. Severe cerebral injury was identified in
11% (28/263) of liveborn twins, in 11% (13/118) of TAPS donors, and in 10% (15/145) of TAPS recipients
(p = 0.916). Severe cerebral injury was diagnosed based on intraventricular hemorrhage ≥ Grade 3
(n = 15), cystic periventricular leukomalacia ≥Grade 2 (n = 5), (post-hemorrhagic) ventricular dilatation
(n = 6), porencephalic or parenchymal cysts (n = 3), arterial infarction (n = 1), and other severe lesions
associated with adverse outcome (n = 1). Ischemic limb injury did not occur in this cohort of post-laser
TAPS twins.
Table 4. Perinatal outcome in the post-laser twin anemia polycythemia sequence.
Post-Laser TAPS
(N = 164 Pregnancies;
328 Fetuses)
TAPS Donors
(N = 164 Fetuses)
TAPS Recipients
(N = 164 Fetuses) † p-Value
GA at birth 31.7 (28.6–33.7; 19.0–41.3)
Fetal demise † 56/327 (17) 43/164 (26) 13/163 (8) <0.001
Spontaneous 33/327 (10) 25/164 (15) 8/163 (5) <0.001
Intended 23/327 (7) 18/164 (11) 5/163 (3) 0.007
Neonatal mortality 27/271 (10) 18/121 (15) 9/150 (6) 0.008
Perinatal mortality (overall) † 83/327 (25) 61/164 (37) 22/163 (14) <0.001
Perinatal mortality (spontaneous) † 60/327 (18) 43/164 (26) 17/163 (10) <0.001
Severe neonatal morbidity ‡ 105/263 (40) 51/118 (43) 54/145 (37) 0.568
Respiratory distress syndrome 88/263(34) 42/118 (36) 46/145 (32) 0.945
Patent ductus arteriosus 20/263 (8) 11/118 (9) 9/145 (6) 0.278
Necrotizing enterocolitis 6/263 (2) 4/118 (3) 2/145 (1) 0.275
Retinopathy of prematurity 9/263 (3) 6/118 (5) 3/145 (2) 0.165
Amniotic band syndrome 3/263 (1) 2/118 (2) 1/145 (1) 0.451
Severe cerebral injury 28/263 (11) 13/118 (11) 15/145 (10) 0.916
Birth weight (g) § 1390 ± 567 1346 ± 525 1533 ± 588 <0.001
Severe growth restriction (bw < p3) § 62/270 (23) 31/121 (26) 31/149 (21) 0.267
Mild growth restriction (bw < p10) § 122/270 (45) 60/121 (50) 61/149 (41) 0.061
Data are presented as the means ± SD, medians (IQR), or n/N (%). † One missing value (1 post-laser TAPS recipient
with unknown perinatal outcome). ‡ Nine missing values (same as “†” plus 4 cases with unknown neonatal
morbidity info and 4 cases that died shortly after birth). § Two missing values (same as “†” plus one case with
missing birth weight). TAPS, twin anemia polycythemia sequence; GA, gestational age; bw, birth weight.
In cases that were diagnosed with TAPS at birth (72%; 76/106), the median inter-twin hemoglobin
difference was 12.6 g/dL (IQR: 10.3–15.1, range: 8.2–21.7), and the median reticulocyte count ratio was
2.7 (IQR: 2.3–3.9). At birth, 68% (52/76) of donors needed a blood transfusion to treat anemia, and 49%
(37/76) of recipients needed a PET to treat polycythemia. In total, 33% (25/76) had Stage 1 postnatal
TAPS, 34% (26/76) Stage 2, 20% (15/76) Stage 3, 11% (8/76) Stage 4, and 1% (1/76) Stage 5 postnatal TAPS.
Univariate risk factor analysis showed that spontaneous perinatal mortality was significantly
associated with Quintero Stage 3 (OR = 3.6, 95%CI 1.1–12.0, p = 0.039), antenatal TAPS Stage 4 (OR = 6.1,
95%CI 1.8–20.4, p = 0.003), TAPS donor status (OR = 3.7, 95%CI 2.2–6.3, p < 0.001), and GA at birth
(OR = 0.8, 95%CI 0.7-1.0, p = 0.006). There was no strong correlation between the risk factors (Quintero
stage–TAPS donor status (R < 0.001, p = 1.000); Quintero stage–antenatal TAPS stage (R = 0.078,
p = 0.187); TAPS donor status–antenatal TAPS stage (R = −0.005, p = 0.931); Quintero stage–GA at birth
(R = −0.022, p = 0.701); TAPS donor status–GA at birth (R < 0.001, p = 0.998); antenatal TAPS stage–GA
at birth (R = −0.005, p = 0.931)), so all parameters were included in the multivariate analysis. In the
multivariate analysis, antenatal TAPS Stage 4 (OR = 6.1, 95%CI 1.4–26.0, p = 0.015), TAPS donor status
(OR = 4.2, 95%CI 2.1–8.3, p < 0.001), and GA at birth (OR = 0.8, 95%CI 0.7–0.9, p = 0.001) were identified
as independent risk factors for spontaneous perinatal mortality. Univariate risk factor analysis showed
that severe neonatal morbidity was significantly associated with GA at birth (OR = 1.5, 95%CI 1.3–1.8,
p < 0.001) and Quintero Stage 2 (OR = 3.2 95%CI 1.1–9.7, p = 0.038). Both parameters were included in
multivariate risk factor analysis as no correlation was found between the two (R = −0.022, p = 0.701).
Multivariate risk factor analysis revealed that only GA at birth was an independent risk factor for
severe neonatal morbidity (OR = 1.5, 95%CI 1.3–1.7, p < 0.001). More details on the risk analyses for
perinatal mortality and severe neonatal morbidity are presented in Tables A2 and A3 of Appendix B.
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4. Discussion
This was the first large international study investigating management and outcome in post-laser
TAPS twins. Our study showed that post-laser TAPS generally developed within one month after laser
for TTTS, but could be detected up to 17 weeks after laser intervention. Management for post-laser
TAPS was mostly expectant, but varied considerably, highlighting the lack of consensus for optimal
treatment. In this cohort, perinatal outcome was poor, particularly due to high perinatal mortality rates
in TAPS donors. This study provided important information for clinicians involved in the care for TTTS
twins treated with laser surgery and might contribute to a better understanding of post-laser TAPS.
This is the first study that gives a clear overview of the time of onset of post-laser TAPS and
and shows that there is a wide range in timing of presentation. This variation might be attributed
to two factors. First, reversal of the donor-recipient role could result in a slower development of
post-laser TAPS. Possibly, former TTTS recipients that became TAPS donors may be protected against
anemia for a longer period of time due to the excess of blood they received during TTTS. In contrast,
former TTTS donors that became TAPS donors might suffer sooner from anemia due to their relatively
hypovolemic state. Alternatively, TAPS might develop later in cases with compensating blood supply,
allowed by VA, AA, or VV anastomoses. Our results showed that half of the post-laser TAPS cases
presented within two weeks after laser surgery for TTTS. Although all cases in this study had signs
of ongoing TAPS after the first week, spontaneous normalization of a large MCA-PSV discordancy
after laser surgery has also been reported in previous literature [12,20]. Importantly, a large MCA-PSV
difference shortly after laser might in some cases be the result of fetal hemodynamic re-equilibration
after intervention, rather than the onset of post-laser TAPS due to the presence of a patent anastomosis.
Consequently, intervening directly within 1-2 weeks after laser surgery in these cases could lead to
unnecessary treatment since there is no ongoing transfusion. Therefore, close follow-up ultrasound
examination to identify persistence or progression of a MCA-PSV discrepancy after the first weeks after
laser surgery is recommended to confirm the diagnosis of post-laser TAPS and prevent unnecessary
intervention and exposure to iatrogenic risks.
Our study demonstrated that 81% of the surgeons initially thought that the laser for TTTS was
complete. This “low index of suspicion” causes TAPS to often occur unexpectedly and shows that
operator-reported completeness cannot be relied upon. Interestingly, approximately a third of post-laser
TAPS twins were treated for TTTS with the Solomon technique. This illustrated that, although the
Solomon technique has been proven to decrease the incidence of post-laser TAPS [2], clinicians should
remain vigilant for the development of this complication even after a complete Solomon line was
thought to be achieved. In agreement with the current recommendations of the twin guideline of
the International Society of Ultrasound in Obstetrics and Gynecology [21], we strongly underline the
importance of strict routine MCA-PSV Doppler follow-up examination in TTTS twins treated with
laser surgery during the entire pregnancy to check for the presence of post-laser TAPS.
We found high rates of perinatal mortality, particularly in the TAPS donor, reflecting the detrimental
impact of fetal anemia on perinatal survival. Remarkably, TAPS donors only showed increased risk for
perinatal mortality. After birth, donors and recipients had similar rates of severe neonatal morbidity,
suggesting that neonatal health is more strongly related to the degree of prematurity than TAPS
donor-recipient status. Importantly, this study demonstrated that GA at birth is a strong risk factor
for both perinatal mortality and severe neonatal morbidity in post-laser TAPS twins. Compared to
post-laser TAPS survivors that were previously investigated in the Solomon trial [22], we reported
similar rates of severe neonatal morbidity (38% vs. 39%) and higher rates of perinatal mortality (18%
vs. 26%). Of note, long-term outcome was not investigated in this study, and therefore, a difference in
long-term neurodevelopmental impairment between donors and recipients cannot be precluded.
Post-laser TAPS twins showed an overall more detrimental outcome than spontaneous TAPS
twins [8]. The exact cause of this difference in outcome is not entirely clear, but it is likely to be
multifactorial. The first and most obvious explanation is that post-laser TAPS twins have previously
experienced TTTS, a severe condition itself [23]. Therefore, their fetal condition might already be
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compromised when they start developing TAPS. Given the fact that half of the post-laser TAPS cases
occur within the first two weeks after laser, twins have had only limited time to recover, making them
more prone to decompensation. A second explanation could be found in the angioarchitecture of
placentas of post-laser TAPS twins. This study represents the biggest cohort of injected post-laser TAPS
placentas and confirms previous findings that post-laser TAPS placentas often show only one or a
few placental anastomoses [24]. Additionally, we found that most cases only had unidirectional AV
anastomoses, without compensating flow from VA, AA, or VV anastomoses in the opposite direction.
This might lead to an accelerated deterioration of TAPS, resulting more rapidly in abnormal Doppler
blood flows, hydrops, and fetal death. Interestingly, a minority of post-laser TAPS placentas did
not show residual anastomoses, in spite of the presence of confirmed postnatal TAPS. This could be
explained by suboptimal color dye or by the presence of deep, hidden anastomoses [4,25]. Third, the
choice of antenatal management might have also influenced the condition of post-laser TAPS twins.
Our results showed that treatment for post-laser TAPS was diverse, but that the majority of the group
was managed expectantly or received IUT (± PET); two treatment strategies that are not definitive
in nature and allow the condition to progress. Possibly, laser was considered more challenging or
not feasible in cases that already underwent laser, due to expected reduced visibility, membrane
separation, iatrogenic monoamnionicity, PPROM, or because of the same reasons that caused the laser
to be incomplete in the first place, such as the position of the placenta. Illustratively, we found a high
rate (40%) of residual anastomoses in twins treated with laser reintervention. A detailed evaluation of
differences in perinatal outcome between the various management strategies will be presented in a
separate study [26].
As with all registries, this study was fully dependent on local registrations of post-laser TAPS cases.
In many countries, TTTS cases are sent back to the referring hospital after laser procedure, leaving care
in less experienced hands. As the diagnosis of post-laser TAPS is only reached by adequate MCA-PSV
Doppler examination, hemoglobin and reticulocyte measures, and placental-injection studies, it is likely
that some post-laser TAPS cases have been missed. Nonetheless, this study represented the largest
cohort of post-laser TAPS twins to date and was able to provide valuable insights into management
and outcome in post-laser TAPS.
5. Conclusions
To conclude, post-laser TAPS could occur at any time after laser for TTTS, is managed
heterogeneously, and is associated with poor outcome, particularly in donor twins. Our findings
necessitate further research into the best treatment option for TAPS. To investigate the best treatment
for TAPS adequately, an international randomized controlled trial is needed.
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Appendix A
Table A1. Participating fetal therapy centers and their number of contributed post-laser TAPS cases.
Center Country Post-Laser TAPS Cases
Leiden University Medical Center The Netherlands 66
Children’s Hospital V. Buzzi Milan Italy 17
Necker-Enfants Malades Hospital Paris France 16
Leuven University Hospital Belgium 13
Center Medico-Chirurgical Obstetrical Strasbourg France 10
Mount Sinai Hospital Toronto Canada 10
Saint George’s Hospital London United Kingdom 5
Birmingham Women’s and Children’s NHS Foundation Trust United Kingdom 5
Medical University of Graz Austria 3
Mater Hospital Brisbane Australia 4
University of Texas McGovern Medical School at Houston United States of America 4
V.I. Kulakov National Medical Research Center of Obstetrics,
Gynecology and Perinatology Moscow Russia 4
Karolinska University Hospital Stockholm Sweden 3
Hospital Universitari Vall d’Hebron Barcelona Spain 2
Brugmann University Hospital Belgium 1
University Medical Center Hamburg-Eppendorf Germany 1
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Appendix B
Table A2. Univariate and multivariate risk analysis for spontaneous perinatal mortality in the post-laser twin anemia polycythemia sequence.
Death †
(n = 60/304)
Alive †
(n = 244/304)
Univariate Analysis
OR (95% CI) SE p
Multivariate Analysis OR
(95% CI) SE p
GA at diagnosis TAPS 23.3 ± 3.3 23.7 ± 3.7 1.0 (0.9–1.1) 0.1 0.623
GA at laser TTTS 20.1 ± 2.4 20.8 ± 3.3 0.9 (0.8–1.0) 0.1 0.233
Days between TTTS laser and TAPS 20.9 ± 18.4 21.8 ± 23.1 1.0 (1.0–1.0) 0.0 0.829
Quintero stage for TTTS ‡
1 3/35 (9) 32/35 (91) - * - *
2 27/140 (19) 113/140 (81) 2.5 (0.7–8.5) 0.6 0.139 1.7 (0.4–6.9) 0.7 0.439
3 27/111 (24) 84/111(76) 3.6 (1.1–12.0) 0.6 0.039 3.5 (0.9–13.2) 0.7 0.069
4 2/10 (20) 8/10 (80) 2.8 (0.2–32.4) 1.3 0.418 3.4 (0.3–33.6) 1.2 0.298
Antenatal TAPS stage
1 6/47 (13) 41/47 (87) - * - *
2 12/122 (10) 110/122 (90) 0.9 (0.3–3.2) 0.6 0.864 0.8 (0.2–3.2) 0.7 0.790
3 14/56 (25) 50/56 (75) 2.6 (0.7–9.1) 0.6 0.136 2.6 (0.6–10.3) 0.7 0.182
4 20/46 (44) 26/46 (55) 6.1 (1.8–20.4) 0.6 0.003 6.1 (1.4–26.0) 0.7 0.015
TAPS recipient 17/158 (11) 146/158 (89) - * - *
TAPS donor 43/146 (30) 103/146 (70) 3.7 (2.2–6.3) 0.3 <0.001 4.2 (2.1–8.3) 0.3 <0.001
Persistence of TTTS-TAPS donor-role, no § 25/162 (15) 137/162 (85) - *
Persistence of TTTS-TAPS donor-role, yes § 34/137 (25) 103/137 (77) 1.8 (1.0–3.5) 0.3 0.061
Antenatal therapy
Expectant management 27/124 (22) 97/124 (78) - *
Delivery 4/18 (22) 14/18 (78) 1.4 (0.3–4.2) 0.6 0.622
IUT (± PET) 16/81 (20) 72/81 (82) 0.9 (0.4–1.9) 0.4 0.893
Laser surgery 9/44 (21) 38/44 (79) 1.0 (0.3–2.8) 0.5 0.942
Selective feticide (co-twin) 0/11 (0) 11/11 (100) 0.3 (0.0–2.9) 1.1 0.330
GA at birth 29.5 ± 5.0 31.6 ± 3.1 0.8 (0.7–1.0) 0.1 0.006 0.8 (0.7–0.9) 0.1 0.001
Values are the odds ratios (OR) (95% confidence intervals (CI)), the standard error (SE), and the p-value. * Set to zero as the reference. † Twenty-three of 327 cases were excluded based on
selective feticide or termination of pregnancy. ‡ Five cases had a missing Quintero stage value.§ In 3 cases, persistence of TTS-TAPS donor-role was unknown. ¶ SPSS was not able to
calculate OR for groups in which the event (spontaneous mortality) did not occur; therefore, a correction for non-occurring events was applied, and with this correction, an unaffected child
was changed into an affected child, for all groups. TAPS, twin anemia polycythemia sequence; GA, gestational age; TTTS, twin-twin transfusion syndrome; IUT, intrauterine transfusion;
PET, partial exchange transfusion.
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Table A3. Univariate and multivariate risk analysis for spontaneous perinatal mortality in the post-laser twin anemia polycythemia sequence.
SNM †
(139/429)
No SNM †
(290/429)
Univariate Analysis
OR (95% CI) SE p
Multivariate Analysis OR
(95% CI) SE p
GA at diagnosis TAPS 24.5 ± 3.1 23.4 ± 4.0 0.9 (0.8–1.0) 0.1 0.090
GA at laser TTTS 21.1 ± 2.6 20.6 ± 3.6 0.9 (0.8–1.0) 0.1 0.261
Days between TTTS laser and TAPS 22.3 ± 21.9 22.1 ± 23.9 1.0 (1.0–1.0) 0.0 0.987
Quintero stage for TTTS
1 8/34 (24) 26/34 (76) - * - *
2 64/123 (52) 59/123 (48) 3.2 (1.1–9.7) 0.6 0.038 2.8 (0.9–9.0) 0.6 0.066
3 28/89 (32) 61/89 (68) 1.3 (0.4–4.2) 0.6 0.617 1.3 (0.4–3.9) 0.6 0.690
4 3/10 (30) 3/10 (70) 1.3 (0.2–9.3) 1.0 0.782 1.1 (0.1–10.0) 1.1 0.959
Antenatal TAPS stage
1 18/45 (40) 30/45 (60) - *
2 41/112 (37) 71/112 (63) 1.0 (0.4–2.5) 0.5 0.970
3 16/45 (36) 29/45 (64) 0.7 (0.2–2.2) 0.6 0.570
4 17/32 (53) 15/32 (47) 1.6 (0.5–5.0) 0.6 0.381
TAPS recipient 54/145(37) 91/145 (63) - *
TAPS donor 51/118 (43) 67/118 (57) 1.1 (0.8–1.5) 0.2 0.568
Persistence of TTTS-TAPS donor-role, no 47/139 (34) 92/139 (66) - *
Persistence of TTTS-TAPS donor-role, yes 58/120 (48) 62/120 (52) 1.6 (0.9–3.0) 0.3 0.116
Antenatal therapy
Expectant management 34/100 (34) 66/100 (66) - *
Delivery 9/17 (53) 8/17 (47) 2.1 (0.6–8.1) 0.7 0.270
IUT (± PET) 34/72 (47) 38/72 (53) 1.7 (0.8–3.7) 0.4 0.158
Laser surgery 12/37 (32) 25/37 (68) 1.1 (0.4–2.9) 0.5 0.851
Selective feticide 3/11 (27) 8/11 (73) 0.7 (0.2–3.2) 0.7 0.720
GA at birth 29.4 ± 2.6 32.9 ± 2.8 1.5 (1.3–1.7) 0.1 <0.001 1.5 (1.3–1.7) 0.1 <0.001
Severe growth restriction, no 81/200 (41) 119/200 (60) - *
Severe growth restriction, yes 24/62 (39) 38/62 (61) 1.3 (0.8–2.2) 0.3 0.351
Postnatal TAPS, no 23/58 (40) 35/58 (60) - *
Postnatal TAPS, yes 64/151 (42) 87/151(58) 1.1 (0.5–2.5) 0.4 0.800
Values are the odds ratios (OR) (95% confidence intervals (CI)), the standard error (SE), and the p-value. * Set to zero as the reference. † Nine missing values (6 cases with unknown
neonatal outcome and 3 neonates that died shortly after birth). SNM, severe neonatal morbidity; TAPS, twin anemia polycythemia sequence; GA, gestational age; IUT, intrauterine
transfusion; PET, partial exchange transfusion.
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